Taketoshi Mizutani
Overview
Explore the profile of Taketoshi Mizutani including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
50
Citations
1025
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Ishizaka A, Tamura A, Koga M, Mizutani T, Yamayoshi S, Iwatsuki-Horimoto K, et al.
Microbiol Spectr
. 2024 Dec;
13(1):e0099824.
PMID: 39656008
This study compared intestinal DNA phage dynamics and gut microbiota changes observed at the onset of coronavirus disease 2019 (COVID-19). The study participants included 19 healthy individuals and 19 patients...
2.
Ishizaka A, Koga M, Mizutani T, Suzuki Y, Matano T, Yotsuyanagi H
BMC Microbiol
. 2024 Jul;
24(1):274.
PMID: 39044127
Background: Person with human immunodeficiency virus type-1 (PWH) are prone to chronic inflammation due to residual viral production, even with antiretroviral therapy (ART), which increases the risk of age-related diseases....
3.
Mizutani T, Ishizaka A
FEBS Lett
. 2024 Jul;
598(15):1909-1918.
PMID: 38955545
The poliovirus (PV) enters the central nervous system (CNS) via the bloodstream, suggesting the existence of a mechanism to cross the blood-brain barrier. Here, we report that PV capsid proteins...
4.
Runtuwene L, Parbie P, Mizutani T, Ishizaka A, Matsuoka S, Abana C, et al.
Front Microbiol
. 2024 Mar;
15:1359402.
PMID: 38426062
Human immunodeficiency virus (HIV) 1 infection is known to cause gut microbiota dysbiosis. Among the causes is the direct infection of HIV-1 in gut-resident CD4 T cells, causing a cascade...
5.
Ishizaka A, Koga M, Mizutani T, Yamayoshi S, Iwatsuki-Horimoto K, Adachi E, et al.
BMC Microbiol
. 2024 Jan;
24(1):6.
PMID: 38172680
Background: People living with HIV (PLWH) with chronic inflammation may have an increasing risk for coronavirus disease 2019 (COVID-19) severity; however, the impact of their gut microbiota on COVID-19 is...
6.
Kashima Y, Mizutani T, Okimoto Y, Maeda M, Musashino K, Nishide R, et al.
DNA Res
. 2023 Sep;
30(5).
PMID: 37712596
Understanding the factors driving the spread and evolution of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) at the local, regional, national, and international levels is important in protecting against future...
7.
Ishizaka A, Koga M, Mizutani T, Uraki R, Yamayoshi S, Iwatsuki-Horimoto K, et al.
Virol J
. 2023 Jul;
20(1):146.
PMID: 37443091
Background: The mucosa serves as the first defence against pathogens and facilitates the surveillance and elimination of symbiotic bacteria by mucosal immunity. Recently, the mRNA vaccine against SARS-CoV-2 has been...
8.
Abana C, Kushitor D, Asigbee T, Parbie P, Ishikawa K, Kiyono H, et al.
BMC Public Health
. 2023 Jun;
23(1):1051.
PMID: 37264375
Background: The 95-95-95 UNAIDS global strategy was adapted to end the AIDS epidemic by 2030. The target is based on the premise that early detection of HIV-infected persons and linking...
9.
Ikeuchi K, Tsutsumi T, Ishizaka A, Mizutani T, Sedohara A, Koga M, et al.
Gut Pathog
. 2023 Mar;
15(1):14.
PMID: 36945059
Background: Rifaximin is a poorly absorbed broad-spectrum antibiotic used for hepatic encephalopathy. Although increased Lactobacillaceae and decreased Bacteroidetes abundance are characteristic of hepatic encephalopathy, rifaximin does not dramatically alter the...
10.
Kashima Y, Mizutani T, Nakayama-Hosoya K, Moriyama S, Matsumura T, Yoshimura Y, et al.
Sci Rep
. 2023 Feb;
13(1):1935.
PMID: 36732528
SARS-CoV-2 continues to spread worldwide. Patients with COVID-19 show distinct clinical symptoms. Although many studies have reported various causes for the diversity of symptoms, the underlying mechanisms are not fully...